2018.Sep.28
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
Date of occurrence of the event: Sept 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study Countermeasures: N/A Any other matters that need to be […]
This article is password protected.
To view the content, please enter your password in the field below